Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT00848926 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)

Study Title
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma (NCT00848926)

Trial Description
This is a single-arm, open-label, multicenter, pivotal clinical trial to evaluate the efficacy and safety of brentuximab vedotin (also known as SGN-35) as a single agent in patients with relapsed or refractory Hodgkin lymphoma.

This trial is sponsored by Millennium Pharmaceuticals/Seattle Genetics. [1]

Study Data

  • Condition: Hodgkin Disease
  • Interventions:
  • Phase: II
  • Enrollment: 102
  • Start: February 2009
  • Completion: May 2015
  • Last verified: June 2015

Study Schematic

Screen Shot 2016-07-18 at 4.58.05 PM

Click here to Return to Drug map


Last Editorial review: July 18, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar